Showing results (201-210 of 295) with videos related to

Sort By:
Pageof 30
Investigational New Drugs|December 22, 2015
A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041)Joanne W Chiu, Sebastien J Hotte, Christian K Kollmannsberger, et al.
JNCI Cancer Spectrum|May 31, 2021
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With ImmunotherapyDaniel V Araujo, Ao Wang, Dax Torti, et al.
JAMA Oncology|November 4, 2021
Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic StudiesSamantha Brown, Jessica A Lavery, Ronglai Shen, et al.
European Urology Focus|February 12, 2018
A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in NonseminomaRicardo Leão, Madhur Nayan, Nahid Punjani, et al.
Investigational New Drugs|July 18, 2013
A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumorsIvan Diaz-Padilla, Hal Hirte, Amit M Oza, et al.
Breast Cancer Research and Treatment|November 28, 2017
Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancerRossanna C Pezo, Tom W Chen, Hal K Berman, et al.
Nature Communications|February 21, 2025
Longitudinal evaluation of circulating tumor DNA in patients undergoing neoadjuvant therapy for early breast cancer using a tumor-informed assayMitchell J Elliott, Philippe Echelard, Christodoulos Pipinikas, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 21, 2020
A Canadian approach to the regionalization of testis cancer: A reviewGregory J Nason, Lori A Wood, Robert A Huddart, et al.
BMC Medical Genomics|August 11, 2018
Additional germline findings from a tumor profiling programNeda Stjepanovic, Tracy L Stockley, Philippe L Bedard, et al.
Pageof 30